About · Contact us · Terms of use · Dr. T
|
Raw foods, Professional quality supplements, preventive medicine products, healthy, ecological home & body goods and more. |
 |
|
Ecopolitan's Minneapolis Restaurant is 100% Organic Vegan Raw restaurant, bar & gallery: "For Your Health, the Earth, & the Taste!" |
 |
(612)-870-2974 Ecopolitan's Eco-Healing activities allow you to treat common health conditions with clinical nutrition, eco-diet & lifestyle. |
 |
|
Learn about lectures, meetings, community activities and events, and join a number of exciting eco-adventures. |
 |
|
Your network of Ecological Hostels, Retreats and Accommodation Solutions. |
 |
|
Your definitive science-based guide for protecting yourself and your loved ones from electromagnetic pollution. |
 |
References
1. Carter, J., et al. Amount and distribution of dietary protein affects clinical response to levodopa in Pardinson's disease. Neurology 39:552-556, 1989
2. Tsui, J., et al. The effect of dietary protein on the efficacy of L-dopa: A double blind study. Neurology 39:549-552, 1989
3. Anderson, C., et at. Dietary factors in Parkinson's disease: The role of food groups and specific foods. Mov Disord 14(1):21-21, 1999
4. Bruce-Keller, A.J., et al. Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann Neurol 45 (1):8-15, 1999.
5. De Rijk, M.C., et al. Dietary antioxidants and Parkinson's disease: The Rotterdam Study. Arch Neurol 54(6): 762-765, 1997.
6. Fahn, S., et al. Experience with tranylcypromine in early Parkinson's disease. J Neural Transm 52(suppl.):49-61, 1998.
7. Ben-Shlomo, Y. The epidemiology of Parkinson's disease. Baillieres Clin Neurol 6(1): 55-68, 1997.
8. Checkoway, H. Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 10(3): 327-336, 1999.
9. Gorell, J.M., et al. Occupational exposure to manganese, copper, lead, iron, mercury, and zinc and the risk of Parkinson's disease. Neurotoxicology 20(2-3):239-247, 1999.
10. Bhatt, M.H., et al. Acute and reversible parkinsonism due to organophosphate pestilcide intoxification: Five cases. Neurology 52(7): 1467-1471, 1999.
11. Kuopio, A.M., et al. Changing epidemiology of Parkinson's disease is southwestern Finland. Neurology 52(2): 302-308, 1999.
12. Ghen, M.J. D.O, Ph.D., and Melindez M., N.D. Protocol for Parkinson's Disease. American Journal of Natural Medicine Vol.5, No. 9, November 1998.
13. Werbach, M. Nutrktional Influences on Illness. Tarzana: Third Line Press, 1993.
14. Beal, M.F., et al. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 783(1):109-114, 1998.
15. Fahn, S. An open trial of high dosage antioxidants in early Parkinson's disease. Am J Clin Nutr 53:380-381, 1991.
16. Critchley, E.M.R. Everning primrose oil (Efamol) in parkinsonism and other tremors: A preliminary study. In: Horrobin, D.F. (ed.) Clinical Uses of Essential Fatty Acids. Montreal: Eden Press, 1992, pp. 205-208.
17. Surtess, r, et al. L-3,4,-dihydroxyphenylalanine lowers central nervous system S-adenosyl-methionine concentrations in humans. J Neurol Neurosurg Psychaitry 53(7): 569-572, 1990.
18. mythies, J.R., et al. Treatment of Parkinson's disease with L-methionine. South Med J 77:1577, 1984.]
19. Bender, D.A., et al. Niacin depletion in parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clin Sci 56910: 89-93, 1979.
20. Black, M.J., et al. Nicotinic acid or N-methyl nicotinamide prolongs elevated brain dopa and dopamine in L-dopa treatment. Biochem Med Metab Biol 36(2): 244-251, 1986.
21. Heller, B., et al. Therpeutic action of D-phenylalanine in Parkinson's disease. Arzeim Forsch 26:577-579, 1976
22. Sandyk, R., at al, L-tryptoplan supplementation in Parkinson's disease. Int j Neurosci 45(3-4): 215-219, 1989.
23. Coppen, A.., et al. Levodopa an L-tryptophan therapy in Parkinson's. Lancet 1:654-657, 1972.
24. Lan, J., et al. Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transm 104(6-7): 649-660, 1997.
25. Logroscine, g., et al. dietary iron, animal fat, and risk of Parkinson's disease. Mov Disord 13(1): 13-16, 1998.
26. Utti, R.J., et al. Regional metal concentrations in Parkinson's disease, other chronic neurological diseases and control brains. Can J Neurol Sci 16(3): 310-314, 1989.
27. Zayed, J., et al. enviromental factors in the etiology of Parkinson's disease. Can J Neurol Sci 17(3):286-291, 1990.
28. Florence, T.M., et al. Neurotoxicity of manganese [letter]. Lancet i:363, 1988.
29. Pall, H.S., et al. Raised cerebrospinal-fluid copper concentrations in Parkinson's desease. Lancet ii:238-241, 1987.
30. Dexter, D.T., et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52(6):1830-1836, 1989.
31. Schelosky, L., et al. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry, 58(5):639-640, 1995.
32. Steventon, G.B. et al. Xenobiotic Metabolism in Parkinson's Disease. Neurology 39: 893-887, July 1989.
33. Botz, ME. Gesstner, A. Harth, R et al "Altered Redox State of Platelet Coenzyme Q10 in Parkinson's Disease" Journal of Neural Transmitters (2000) 107: 41-48.
34. Natelson BH. Beans a Source of L-Dopa. Lancet 1969; 1:640-641
35. Effects of Coenzyme Q10 in Early Parkinson Disease ARCH NEUROL 2002:59:1541-50.